Cyfuse Biomedical KK

Cyfuse Biomedical KK PEG

The PEG Ratio (Price/Earnings-to-Growth) of Cyfuse Biomedical KK (4892.T) as of Nov 2, 2026 is 2.74.

PEG

2.74

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Cyfuse Biomedical KK is 2021 2.74 . PEG Ratio (Price/Earnings-to-Growth) of Cyfuse Biomedical KK was 2020 - . It decreases by % lower compared to the previous year.

The Cyfuse Biomedical KK PEG history

The Cyfuse Biomedical KK PEG history
YEARPEGYoY
2.74—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cyfuse Biomedical KK Stock analysis

What does Cyfuse Biomedical KK do? Cyfuse Biomedical KK develops and manufactures cell regenerative systems, focusing on regenerative medicine products and drug discovery support tools. The company sells three-dimensional cell stacking system equipment, which includes basic technology and apply technology for cell product development. Its primary customers are pharmaceutical companies seeking drug discovery support and institutions requiring regenerative medicine solutions. The firm generates revenue through the sale of equipment and contract research services for cell products in the regenerative medicine field. Cyfuse Biomedical KK's business model centers on developing and selling three-dimensional cell stacking systems, which are used as tools for drug discovery support. The company also provides contract research services for cell products, targeting pharmaceutical companies and research institutions. Revenue streams include equipment sales and contract research, with a focus on regenerative medicine applications and drug discovery support. The company's product portfolio includes three-dimensional cell stacking system equipment, which incorporates basic technology and apply technology for cell product development. These systems are sold to pharmaceutical companies and research institutions for use in regenerative medicine and drug discovery. The firm's revenue is derived from the sale of equipment and the provision of contract research services in the regenerative medicine sector. Cyfuse Biomedical KK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyfuse Biomedical KK stock

PEG Ratio (Price/Earnings-to-Growth) of Cyfuse Biomedical KK is 2.74 in 2021.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Cyfuse Biomedical KK since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Cyfuse Biomedical KK with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cyfuse Biomedical KK

All Key Metrics — Cyfuse Biomedical KK